Advanced search
Publication Cover
Future Oncology Volume 5, 2009 - Issue 9
Submit an article Journal homepage
500
Views
0
CrossRef citations to date
0
Altmetric
Review

Molecular Mechanisms of Castration-Resistant Prostate Cancer Progression

Smitha S Dutta University of California School of Medicine at Davis, CA, USAView further author information
&
Allen C Gaob Department of Urology and Cancer Center, Research III Bldg, Suite 1300, University of California School of Medicine at Davis, 4645 2nd Ave, Sacramento, CA95817, USA. [email protected]Correspondence[email protected]
View further author information
Pages 1403-1413 | Published online: 10 Nov 2009

Bibliography

  • Isaacs JT : Role of androgens in prostatic cancer.Vitam. Horm.49, 433–502 (1994).
  • Trapman J , CleutjensKB: Androgen-regulated gene expression in prostate cancer.Semin. Cancer Biol.8(1), 29–36 (1997).
  • Huggins C , HodgesCV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.CA Cancer J. Clin.22(4), 232–240 (1972).
  • Hobisch A , CuligZ, RadmayrC, BartschG, KlockerH, HittmairA: Distant metastases from prostatic carcinoma express androgen receptor protein.Cancer Res.55(14), 3068–3072 (1995).
  • van der Kwast TH , SchalkenJ, Ruizeveld de WinterJAet al.: Androgen receptors in endocrine-therapy-resistant human prostate cancer.Int. J. Cancer48(2), 189–193 (1991).
  • Huggins CMD , HodgesCV: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate.Cancer Res.19, 293–297 (1941).
  • Dehm SM , TindallDJ: Regulation of androgen receptor signaling in prostate cancer.Expert Rev. Anticancer Ther.5(1), 63–74 (2005).
  • Feldman BJ , FeldmanD: The development of androgen-independent prostate cancer.Nat. Rev. Cancer1(1), 34–45 (2001).
  • Pienta KJ , BradleyD: Mechanisms underlying the development of androgen-independent prostate cancer.Clin. Cancer Res.12(6), 1665–1671 (2006).
  • Arnold JT , IsaacsJT: Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell’s fault.Endocr. Relat. Cancer9(1), 61–73 (2002).
  • Lee SO , LouW, HouM, OnateSA, GaoAC: Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway.Oncogene22(39), 7981–7988 (2003).
  • Lee SO , LouW, HouM, de MiguelF, GerberL, GaoAC: Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.Clin. Cancer Res.9(1), 370–376 (2003).
  • Grossmann ME , HuangH, TindallDJ: Androgen receptor signaling in androgen-refractory prostate cancer.J. Natl Cancer Inst.93(22), 1687–1697 (2001).
  • Shi XB , MaAH, TepperCGet al.: Molecular alterations associated with LNCaP cell progression to androgen independence.Prostate60(3), 257–271 (2004).
  • Chen Q , WatsonJT, MarengoSRet al.: Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.Cancer Lett.244(2), 274–288 (2006).
  • Akira S , TagaT, KishimotoT: Interleukin-6 in biology and medicine.Adv. Immunol.54, 1–78 (1993).
  • Murakami M , HibiM, NakagawaNet al.: IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase.Science260(5115), 1808–1810 (1993).
  • Simpson RJ , HammacherA, SmithDK, MatthewsJM, WardLD: Interleukin-6: structure-function relationships.Protein Sci.6(5), 929–955 (1997).
  • Siegall CB , SchwabG, NordanRP, FitzGeraldDJ, PastanI: Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.Cancer Res.50(24), 7786–7788 (1990).
  • Siegsmund MJ , YamazakiH, PastanI: Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia.J. Urol.151(5), 1396–1399 (1994).
  • Hobisch A , RogatschH, HittmairAet al.: Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue.J. Pathol.191(3), 239–244 (2000).
  • Drachenberg DE , ElgamalAA, RowbothamR, PetersonM, MurphyGP: Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.Prostate41(2), 127–133 (1999).
  • Adler HL , McCurdyMA, KattanMW, TimmeTL, ScardinoPT, ThompsonTC: Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma.J. Urol.161(1), 182–187 (1999).
  • Okamoto M , LeeC, OyasuR: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.Cancer Res.57(1), 141–146 (1997).
  • Hobisch A , EderIE, PutzTet al.: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.Cancer Res.58(20), 4640–4645 (1998).
  • Chen T , WangLH, FarrarWL: Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.Cancer Res.60(8), 2132–2135 (2000).
  • Lou W , NiZ, DyerK, TweardyDJ, GaoAC: Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway.Prostate42(3), 239–242 (2000).
  • Lee SO , LouW, JohnsonCS, TrumpDL, GaoAC: Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway.Prostate60(3), 178–186 (2004).
  • Inoue K , SlatonJW, EveBYet al.: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.Clin. Cancer Res.6(5), 2104–2119 (2000).
  • Araki S , OmoriY, LynDet al.: Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer.Cancer Res.67(14), 6854–6862 (2007).
  • Yang HP , WoodsonK, TaylorPRet al.: Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial.Eur. J. Cancer Prev.15(3), 249–253 (2006).
  • Lee LF , LouieMC, DesaiSJet al.: Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.Oncogene23(12), 2197–2205 (2004).
  • Gujral A , BurtonDW, TerkeltaubR, DeftosLJ: Parathyroid hormone-related protein induces interleukin 8 production by prostate cancer cells via a novel intracrine mechanism not mediated by its classical nuclear localization sequence.Cancer Res.61(5), 2282–2288 (2001).
  • Lehrer S , DiamondEJ, MamkineB, StoneNN, StockRG: Serum interleukin-8 is elevated in men with prostate cancer and bone metastases.Technol. Cancer Res. Treat.3(5), 411 (2004).
  • Schauer IG , ResslerSJ, TuxhornJA, DangTD, RowleyDR: Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia.Urology72(1), 205–213 (2008).
  • Qiu Y , RobinsonD, PretlowTG, KungHJ: Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3‘-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.Proc. Natl Acad. Sci. USA95(7), 3644–3649 (1998).
  • Lee SO , ChunJY, NadimintyN, LouW, GaoAC: Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.Prostate67(7), 764–773 (2007).
  • Yuan TC , VeeramaniS, LinFFet al.: Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.Endocr. Relat. Cancer13(1), 151–167 (2006).
  • Spiotto MT , ChungTD: STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells.Prostate42(3), 186–195 (2000).
  • Deeble PD , MurphyDJ, ParsonsSJ, CoxME: Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.Mol. Cell. Biol.21(24), 8471–8482 (2001).
  • Lee LF , GuanJ, QiuY, KungHJ: Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.Mol. Cell. Biol.21(24), 8385–8397 (2001).
  • Desai SJ , MaAH, TepperCG, ChenHW, KungHJ: Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications.Cancer Res.66(21), 10449–10459 (2006).
  • Jin RJ , WangY, MasumoriNet al.: NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.Cancer Res.64(15), 5489–5495 (2004).
  • Akakura K , BruchovskyN, GoldenbergSL, RenniePS, BuckleyAR, SullivanLD: Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.Cancer71(9), 2782–2790 (1993).
  • Ayala G , TuxhornJA, WheelerTMet al.: Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.Clin. Cancer Res.9(13), 4792–4801 (2003).
  • Rowley DR : What might a stromal response mean to prostate cancer progression?Cancer Metastasis Rev.17, 411–419 (1999).
  • Tuxhorn JA , AyalaGE, RowleyDR: Reactive stroma in prostate cancer progression.J. Urol.166(6), 2472–2483 (2001).
  • Hendriksen PJ , DitsNF, KokameKet al.: Evolution of the androgen receptor pathway during progression of prostate cancer.Cancer Res.66(10), 5012–5020 (2006).
  • Mohler JL , GregoryCW, FordOH3rdet al.: The androgen axis in recurrent prostate cancer.Clin. Cancer Res.10(2), 440–448 (2004).
  • Stanbrough M , BubleyGJ, RossKet al.: Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.Cancer Res.66(5), 2815–2825 (2006).
  • Montgomery RB , MostaghelEA, VessellaRet al.: Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.Cancer Res.68(11), 4447–4454 (2008).
  • Marks LS , MostaghelEA, NelsonPS: Prostate tissue androgens: history and current clinical relevance.Urology72(2), 247–254 (2008).
  • Mostaghel EA , NelsonPS: Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.Best Pract. Res. Clin. Endocrinol. Metab.22(2), 243–258 (2008).
  • Mostaghel EA , PageST, LinDWet al.: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.Cancer Res.67(10), 5033–5041 (2007).
  • Page ST , LinDW, MostaghelEAet al.: Persistent intraprostatic androgen concentrations after medical castration in healthy men.J. Clin. Endocrinol. Metab.91(10), 3850–3856 (2006).
  • Belanger B , BelangerA, LabrieF, DupontA, CusanL, MonfetteG: Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men.J. Steroid Biochem.32(5), 695–698 (1989).
  • Mizokami A , KohE, FujitaHet al.: The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.Cancer Res.64(2), 765–771 (2004).
  • Chun JY , NadimintyN, DuttSet al.: Interleukin-6 regulates androgen synthesis in prostate cancer cells.Clin. Cancer Res.15(15), 4815–4822 (2009).
  • Arnold JT , GrayNE, JacobowitzKet al.: Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells.J. Steroid Biochem. Mol. Biol.111(3–5), 240–246 (2008).
  • Linja MJ , SavinainenKJ, SaramakiOR, TammelaTL, VessellaRL, VisakorpiT: Amplification and overexpression of androgen receptor gene in hormone- refractory prostate cancer.Cancer Res.61(9), 3550–3555 (2001).
  • Dehm SM , SchmidtLJ, HeemersHV, VessellaRL, TindallDJ: Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.Cancer Res.68(13), 5469–5477 (2008).
  • Tepper CG , BoucherDL, RyanPEet al.: Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.Cancer Res.62(22), 6606–6614 (2002).
  • Guo Z , YangX, SunFet al.: A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.Cancer Res.69(6), 2305–2313 (2009).
  • Hu R , DunnTA, WeiSet al.: Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.Cancer Res.69(1), 16–22 (2009).
  • Jagla M , FeveM, KesslerPet al.: A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions.Endocrinology148(9), 4334–4343 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.